Chondrosarcoma in the United States (1973 to 2003): An Analysis of 2890 Cases from the SEER Database

Giuffrida, A Ylenia; Burgueno, Jorge E.; Koniaris, Leonidas G.; Gutierrez, Juan C.; Duncan, Robert C.; Scully, Sean P.

doi:10.2106/jbjs.h.00416

Cited by 317 publications

(303 citation statements)

References 26 publications

Supporting

Mentioning

254

Contrasting

Unclassified

Order By: Relevance

“…These limitations limit our ability to state which factors are the most important determinants of prognosis in this disease. Previous investigations into the prognostic factors associated with conventional chondrosarcoma have identified that histologic grade and margin status have been directly related to patient survival [9]. Neither histologic grade nor margin status was uniformly reported in this patient cohort.…”

Section: Discussionmentioning

confidence: 58%

“…Survival by anatomic location of chondrosarcoma overall has been examined by Giuffrida et al [9]; however, subgroup analysis for mesenchymal chondrosarcoma was not performed. Consistent with previous data, patients with tumors affecting craniofacial sites were found to have a more favorable prognosis [4,16,23].…”

Section: Discussionmentioning

confidence: 99%

“…It has been associated with late recurrence and metastasis with reports of tumors recurring over 20 years from initiation of primary treatment. In comparison to conventional chondrosarcoma, which has a 10-year overall survival rate of 60% to 70% [6,7,9], the mesenchymal subtype is believed to portend a worse prognosis [2,14,17]. The 10-year survivorship of mesenchymal chondrosarcoma has been previously reported as ranging from 20% to 67% [3,8,11,14,15,17,18,21] with cohorts comprised of head and neck tumors or of pediatric patients representing the upper end of this spectrum [4,16,23].…”

Section: Introductionmentioning

confidence: 99%

“…Tumor grade, extent of surgical margins, and the presence of distant disease have all been associated with worse outcomes in conventional chondrosarcoma [9]. However, analysis of the effects of these variables on the prognosis of mesenchymal chondrosarcoma has been limited, and differences in survival between skeletal and extraskeletal mesenchymal chondrosarcoma have not been well defined [2,8,11].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Schneiderman

Kliethermes

Nystrom

2017

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Studies suggest that mesenchymal chondrosarcoma is associated with a poorer prognosis and a higher proportion of extraskeletal tumors than conventional chondrosarcoma. However, these investigations have been small heterogeneous cohorts, limiting analysis of prognostic factors. Questions/purposes (1) What is the 5-and 10-year survival rate of patients diagnosed with mesenchymal chondrosarcoma? (2) What is the effect of demographic and tumor characteristics on survival in patients with mesenchymal chondrosarcoma? Methods The Surveillance, Epidemiology, and End Results (SEER) database was used to identify all patients diagnosed with mesenchymal chondrosarcoma from 1973 to 2011. SEER reports survival data on over 8.2 million patients with cancer and has attained 98% completeness in reporting. Using variables within the database, this study designated each patient's tumor as skeletal or extraskeletal and cranial, axial, or appendicular, respectively. Overall survival (OS) was determined for the entire series as well as each group. Median survival was calculated using KaplanMeier methods. Cox proportional hazards regression was used to determine whether demographic and tumor variables affected survival. Two hundred five patients with mesenchymal chondrosarcoma were identified, including 82 (40%) skeletal and 123 (60%) extraskeletal. Results OS for the entire series was 51% (95% confidence interval [CI], 43%-58%) and 43% (95% CI, 35%-51%) at 5 and 10 years, respectively. No difference in OS was detected between extraskeletal and skeletal tumors. KaplanMeier analyses showed OS was worse for tumors in axial locations compared with appendicular and cranial locations. Appendicular tumors demonstrated an OS of 50% (95% CI, 36%-63%) at 5 years and 39% (95% CI, 26%-52%) at 10 years. OS for axial tumors was 37% (95% CI, 25%-49%) and 31% (95% CI, 20%-43%), whereas it was 74% (95% CI, 59%-84%) and 67% (95% CI, 50%-79%) for cranial tumors at 5 and 10 years, respectively. When controlling for age, sex, tumor origin, and tumor location, the presence of metastasis (hazard ratio [HR], 12.38; 95% CI, 5.75-26.65; p \ 0.001) and 1-cm size increase (HR, 1.16; 95% CI, 1.09-1.23; p \ 0.001) were both independently associated with an increased risk of death. Tumor location showed different behaviors depending on patient age. In comparison to cranial tumors at age 20 years, the HR was 5.56 (95% CI, 1.47-21.05; p = 0.01) for axial tumors and 6.26 (95% CI, 1.54-25.42; p = 0.01) for appendicular tumors. At age 60 years, those ratios were 0.10 (95% CI, 0.02-0.55; p = 0.01) and 0.14 (95% CI, 0.04-0.58; p = 0.01), respectively. Conclusions Our data suggest that extraskeletal tumors are more common than previously reported; however, this factor does not have clear prognostic value. Presence of metastatic disease and increased tumor size are the main Each author certifies that he or she, or a member of his or her immediate family, has no funding or commercial associations (eg, consultancies, stock ownership, equity interest, paten...

show abstract

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Schneiderman

Kliethermes

Nystrom

2017

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…Despite improvements in diagnostic modalities and surgical techniques, there has not been an improvement in survival of patients with chondrosarcoma over the past 30 years, according to an analysis of US National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) data [7]. To improve the outcome of patients, it seems important to determine how to optimize the treatment of patients who develop recurrence of disease.…”

Section: Introductionmentioning

confidence: 99%

Sixty Percent 10-year Survival of Patients With Chondrosarcoma After Local Recurrence

Lin

Alfawareh

Takeuchi

et al. 2012

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Chondrosarcoma is treated primarily by surgery. The prognosis of patients after local recurrence is not well defined. Both the survival of patients and the risk of further local relapse after surgical treatment of local recurrence have yet to be established. Questions/purposes We determined survival after local recurrence of chondrosarcoma, the rate of further local recurrences, and prognostic factors predicting survival. Patients and Methods We retrospectively reviewed 52 patients treated for locally recurrent conventional chondrosarcoma between 1975 and 2008. All patients had nonmetastatic disease at the time of diagnosis. There were 36 males and 16 females with a median age of 39 years (range, 16-79 years). We analyzed variables affecting overall and disease-free survival. The minimum followup was 12 months unless patients died of disease before 12 months (median, 68 months; range, 4-387 months).Results Thirty patients developed their first local recurrence in axial locations, while 22 developed recurrence in the appendicular skeleton. After local recurrence, overall survival was 74% at 5 years and 60% at 10 years. The mean number of local recurrences was three (range, 1-14).

show abstract

Intralesional treatment versus wide resection for central chondrosarcoma grade I in the long bones

Dierselhuis

Stevens

Jutte

2013

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Chondrosarcoma in the United States (1973 to 2003): An Analysis of 2890 Cases from the SEER Database

Cited by 317 publications

References 26 publications

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database

Sixty Percent 10-year Survival of Patients With Chondrosarcoma After Local Recurrence

Intralesional treatment versus wide resection for central chondrosarcoma grade I in the long bones

Contact Info

Product

Resources

About